Unknown

Dataset Information

0

Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation.


ABSTRACT: Targeting oxidative phosphorylation (OXPHOS) is a promising strategy to improve treatment outcomes of acute myeloid leukemia (AML) patients. IACS-010759 is a mitochondrial complex I inhibitor that has demonstrated preclinical antileukemic activity and is being tested in Phase I clinical trials. However, complex I deficiency has been reported to inhibit apoptotic cell death through prevention of cytochrome c release. Thus, combining IACS-010759 with a BH3 mimetic may overcome this mechanism of resistance leading to synergistic antileukemic activity against AML. In this study, we show that IACS-010759 and venetoclax synergistically induce apoptosis in OXPHOS-reliant AML cell lines and primary patient samples and cooperatively target leukemia progenitor cells. In a relatively OXPHOS-reliant AML cell line derived xenograft mouse model, IACS-010759 treatment significantly prolonged survival, which was further enhanced by treatment with IACS-010759 in combination with venetoclax. Consistent with our hypothesis, IACS-010759 treatment indeed retained cytochrome c in mitochondria, which was completely abolished by venetoclax, resulting in Bak/Bax- and caspase-dependent apoptosis. Our preclinical data provide a rationale for further development of the combination of IACS-010759 and venetoclax for the treatment of patients with AML.

SUBMITTER: Liu F 

PROVIDER: S-EPMC7564145 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation.

Liu Fangbing F   Kalpage Hasini A HA   Wang Deying D   Edwards Holly H   Hüttemann Maik M   Ma Jun J   Su Yongwei Y   Carter Jenna J   Li Xinyu X   Polin Lisa L   Kushner Juiwanna J   Dzinic Sijana H SH   White Kathryn K   Wang Guan G   Taub Jeffrey W JW   Ge Yubin Y  

Cancers 20200824 9


Targeting oxidative phosphorylation (OXPHOS) is a promising strategy to improve treatment outcomes of acute myeloid leukemia (AML) patients. IACS-010759 is a mitochondrial complex I inhibitor that has demonstrated preclinical antileukemic activity and is being tested in Phase I clinical trials. However, complex I deficiency has been reported to inhibit apoptotic cell death through prevention of cytochrome c release. Thus, combining IACS-010759 with a BH3 mimetic may overcome this mechanism of re  ...[more]

Similar Datasets

| S-EPMC7352446 | biostudies-literature
| S-EPMC5657469 | biostudies-literature
| S-EPMC4608389 | biostudies-literature
| S-EPMC5613053 | biostudies-literature
| S-EPMC9021200 | biostudies-literature
| S-EPMC5984704 | biostudies-literature
| S-EPMC3595363 | biostudies-literature
| S-EPMC6858954 | biostudies-literature
| S-EPMC7581748 | biostudies-literature
| S-EPMC7775779 | biostudies-literature